Novo-Nordisk A/S
Symbol: NVO (NYSE)
53.41
▲ (0.34%) 0.182
Company Description:
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Key Stats
- Today's Open: $53.41
- Today's High: $53.644
- Today's Low: $52.857
- Today's Volume: 5.33M
- Yesterday Close: $53.23
- Yesterday High: $53.46
- Yesterday Low: $52.38
- Yesterday Volume: 9.33M
- Last Min Volume: 6.72K
- Last Min High: $53.404
- Last Min Low: $53.387
- Last Min VWAP: $53.3922
Company Profile
- Name: Novo-Nordisk A/S
- Website: https://www.novonordisk.com
- Listed Date: 1981-04-30
- Location: ,
- Market Status: Active
- CIK Number: 0000353278
- SIC Code:
- SIC description:
- Market Cap: $236.52B
- Round Lot: 100
- Outstanding Shares: 4.44B
- Asset Type: ADRC
RECENT FILINGS FOR NVO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-21 | 6-K | View |
| 2025-10-21 | 6-K | View |
| 2025-10-21 | SCHEDULE 13G/A | View |
| 2025-10-09 | 6-K | View |
| 2025-09-10 | 6-K | View |
| 2025-08-19 | 6-K | View |
| 2025-08-18 | 6-K | View |
| 2025-08-14 | 6-K | View |
| 2025-08-08 | 6-K | View |
| 2025-08-08 | 6-K | View |
| 2025-08-06 | 6-K | View |
| 2025-08-04 | 6-K | View |
| 2025-07-29 | 6-K | View |
| 2025-07-29 | 6-K | View |
| 2025-06-27 | 11-K | View |
| 2025-06-27 | 11-K | View |
| 2025-06-13 | 6-K | View |
| 2025-05-30 | 144 | View |
| 2025-05-22 | SD | View |
| 2025-05-16 | 6-K | View |
Latest News on NVO